Skip to the page
Get started – free

Data / Research funding / Neuroblastoma

Neuroblastoma: 192 NIH awards ($401.8M) to 91 organizations

192 NIH awards ($401.8M) in the NIH spending category Neuroblastoma, to 91 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.

SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.

Get awards on NeuroblastomaWatch Neuroblastoma
Topic
NIH spending category

Awards

192 awards in the window.

AwardAgencyInstitute or divisionFiscal yearAmount in windowStartEndPrincipal investigatorSource
COG NCTN Year 12 BIQSFP Progress ReportNIHNational Cancer Institute2021 to 2025$141,250,012April 11, 2014February 28, 2026HAWKINS, DOUGLAS S.reporter.nih.gov
Children's Oncology GroupNIHNational Cancer Institute2023 to 2025$31,354,180March 1, 2023February 28, 2026ALONZO, TODD Areporter.nih.gov
Children's Oncology Group NCI Community Oncology Research Program (NCORP) Research Base grantNIHNational Cancer Institute2021 to 2025$27,607,459June 1, 2025July 31, 2026ROTH, MICHAEL E.reporter.nih.gov
Histidine phosphorylation as a new target for cancer therapyNIHNational Cancer Institute2021 to 2025$5,690,698September 18, 2019August 31, 2026HUNTER, TONY R.reporter.nih.gov
Pediatric Solid Tumor Microenvironment AtlasNIHNational Cancer Institute2024 to 2025$5,678,350September 1, 2024August 31, 2029ASGHARZADEH, SHAHABreporter.nih.gov
U24-Uncovering the Shared Genetic Origins of Childhood Cancer and Structural Birth Defects Through Enhanced Data Integration and Analysis with the CFDE Data Distillery Knowledge Graph.NIHOffice of the Director, National Institutes of Health2024 to 2025$4,408,884September 19, 2024August 31, 2027TAYLOR, DEANNE MARIEreporter.nih.gov
NextGen - CRINIHNational Cancer Institute2022 to 2025$3,968,330June 1, 2025May 31, 2026BOLLARD, CATHERINE M.reporter.nih.gov
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesNIHNational Cancer Institute2021 to 2025$3,932,444September 30, 2017August 31, 2032MARIS, JOHN Mreporter.nih.gov
Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell levelNIHNational Cancer Institute2022 to 2025$3,840,901September 21, 2022August 31, 2027CALIFANO, ANDREAreporter.nih.gov
NGTC - UCLNIHNational Cancer Institute2022 to 2024$3,627,871June 1, 2024May 31, 2025PULE, MARTINreporter.nih.gov
NCI Pediatric In Vivo Testing Program: NeuroblastomaNIHNational Cancer Institute2021 to 2025$3,549,742July 1, 2021June 30, 2027MOSSE, YAEL Preporter.nih.gov
Psychosocial Risk in Young Survivors of Early Onset Pediatric Cancer: The Role of Physical and Neurocognitive Late EffectsNIHNational Cancer Institute2021 to 2025$3,130,357February 9, 2021January 31, 2027GERHARDT, CYNTHIA Areporter.nih.gov
PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors)NIHNational Cancer Institute2024 to 2025$3,108,431May 1, 2024April 30, 2026STEGMAIER, KIMBERLYreporter.nih.gov
Next Generation GPC2-CARs for MedulloblastomaNIHNational Cancer Institute2024 to 2025$2,781,440September 13, 2024August 31, 2026MACKALL, CRYSTALreporter.nih.gov
Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline GliomaNIHNational Cancer Institute2023 to 2025$2,724,833August 1, 2023July 31, 2028OLSON, JAMES Mreporter.nih.gov
Liquid biopsy approaches to inform neuroblastoma prognosis and disease monitoringNIHNational Cancer Institute2022 to 2025$2,631,965April 11, 2022March 31, 2027APPLEBAUM, MARK ANDREWreporter.nih.gov
Personalized neuroblastoma vaccinesNIHNational Cancer Institute2023 to 2025$2,604,046August 1, 2023July 31, 2028MARIS, JOHN Mreporter.nih.gov
Prodrugs targeting norepinephrine transporter for dual-selective therapy of refractory neuroblastomaNIHNational Cancer Institute2021 to 2024$2,435,800July 1, 2020June 30, 2025CHORNY, MICHAELreporter.nih.gov
The IL-18-IFNγ axis predicts response to immunotherapyNIHNational Cancer Institute2023 to 2025$2,399,099February 1, 2023January 31, 2028GUSTAFSON, HEATHER LEIGH HERDreporter.nih.gov
Developing new therapeutic strategies for pediatric tumors that lack clinically actionable mutationsNIHNational Cancer Institute2021 to 2025$2,360,075March 17, 2021May 31, 2026GEELEHER, PAULreporter.nih.gov
MYCN drives a ferroptotic vulnerability in neuroblastomaNIHNational Cancer Institute2023 to 2025$2,275,338September 1, 2023August 31, 2026FABER, ANTHONY CHARLESreporter.nih.gov
PROTECT - Harnessing PROTEin degradation for Advanced Childhood TumorsNIHNational Cancer Institute2024 to 2025$2,221,836May 1, 2024April 30, 2026GRAY, NATHANAEL SCHIANDERreporter.nih.gov
The role of TRIM37 in driving tumorigenesis and cancer-specific vulnerability to PLK4 inhibitionNIHNational Cancer Institute2022 to 2025$2,153,405June 1, 2022May 31, 2027REGOT, SERGIreporter.nih.gov
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancerNIHNational Cancer Institute2021 to 2024$2,117,272July 28, 2020June 30, 2026LI, WEIreporter.nih.gov
Imaging and manipulating oncoprotein phase separation and compartmentalizationNIHNational Cancer Institute2021 to 2025$2,110,885April 1, 2021February 28, 2026SHU, XIAOKUNreporter.nih.gov
Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for ADNIHNational Institute on Aging2021 to 2023$2,091,868April 1, 2021March 31, 2024JOHN, VARGHESEreporter.nih.gov
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in CancerNIHNational Cancer Institute2021 to 2022$2,071,953August 9, 2016July 31, 2023STEGMAIER, KIMBERLYreporter.nih.gov
A Phase 1b, Open-Label, Study of a Novel Targeted Radiotherapy in Children, Adolescents and Young Adults with Inoperable Relapsed or Refractory High Grade GliomaNIHNational Cancer Institute2022 to 2023$1,999,998September 16, 2022June 30, 2024REILLY, LAURENCEreporter.nih.gov
Spatial genomics analysis of tumor samplesNIHNational Cancer Institute2023 to 2024$1,996,962September 1, 2023August 31, 2025FRIEDA, KIRSTENreporter.nih.gov
Novel Therapeutic Approaches for the Treatment of NeuroblastomaNIHNational Cancer Institute2021 to 2024$1,988,123April 1, 2020March 31, 2026DYER, MICHAEL Areporter.nih.gov
Targeting Syk to enhance anti-tumor immune responses in neuroblastomaNIHNational Institute of Neurological Disorders and Stroke2021 to 2025$1,981,973August 1, 2021April 30, 2026JOSHI, SHWETAreporter.nih.gov
Mechanistic biomarkers to enable Bcl2 inhibitor therapies for neuroblastomaNIHNational Cancer Institute2021 to 2025$1,974,115February 18, 2021January 31, 2026HOGARTY, MICHAEL Dreporter.nih.gov
Elucidating the role of the noncoding genome in neuroblastomaNIHNational Cancer Institute2021 to 2025$1,973,426March 12, 2021February 28, 2027DISKIN, SHARONreporter.nih.gov
Toward Translation of an Immunotherapeutic Nanomedicine for NeuroblastomaNIHNational Cancer Institute2022 to 2025$1,952,176July 1, 2022June 30, 2027WILSON, JOHN TANNERreporter.nih.gov
Image-guided dosimetry-based alpha particle therapy for neuroblastoma.NIHNational Cancer Institute2022 to 2023$1,951,675August 4, 2022July 31, 2025SCHULTZ, MICHAEL KINGreporter.nih.gov
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form DevelopmentNIHNational Cancer Institute2021 to 2022$1,948,791September 1, 2021August 31, 2024KRISHNAN, RAJESHreporter.nih.gov
Mechanisms and small-molecule targeting of SWI/SNF activity in neuroblastomaNIHNational Cancer Institute2022 to 2025$1,853,581July 18, 2022June 30, 2027HODGES, HAMILTON COURTNEYreporter.nih.gov
Robust assays to define telomere maintenance mechanisms as cancer biomarkers.NIHNational Cancer Institute2021 to 2025$1,833,412September 16, 2021August 31, 2027REYNOLDS, CHARLES PATRICKreporter.nih.gov
CAR NKT Cell Immunotherapy of NeuroblastomaNIHNational Cancer Institute2021 to 2025$1,828,377June 12, 2021May 31, 2026METELITSA, LEONID Sreporter.nih.gov
Tumor-derived extracellular vesicles in the pre-metastatic niche.NIHNational Cancer Institute2021 to 2025$1,821,912August 1, 2017August 31, 2029DECLERCK, YVES Areporter.nih.gov
Novel small molecule USP7 Inhibitors for p53 activation and cancer therapyNIHNational Cancer Institute2021 to 2025$1,819,525January 1, 2021August 1, 2025GU, WEIreporter.nih.gov
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapyNIHNational Cancer Institute2023 to 2025$1,788,311July 5, 2023June 30, 2028PATEL, RAVI BHASKERreporter.nih.gov
Ameliorating off-target toxicities of CAR T cells by engineering NOT gatesNIHNational Cancer Institute2022 to 2025$1,777,692August 1, 2022July 31, 2027LIM, WENDELL Areporter.nih.gov
NextGen - CHOPNIHNational Cancer Institute2022 to 2025$1,775,451June 1, 2025May 31, 2026MARIS, JOHN Mreporter.nih.gov
Principles of Speckle-Based Gene RegulationNIHNational Cancer Institute2025$1,749,106August 5, 2025July 31, 2028ALEXANDER, KATHERINE ANNreporter.nih.gov
Targeting allosteric scaffolding functions of Aurora kinase A in cancerNIHNational Cancer Institute2021 to 2025$1,740,140April 1, 2021March 31, 2027LEVINSON, NICHOLAS MARKreporter.nih.gov
Intraoperative dual-labeled molecular tracer to improve surgery on neuroblastomaNIHNational Cancer Institute2023 to 2025$1,724,101July 1, 2023June 30, 2028MALEK, MARCUS M.reporter.nih.gov
Discovery of Small Molecule Ligands for PHD1 Reader Domain of Histone Demethylase KDM5ANIHNational Cancer Institute2021 to 2023$1,722,094July 1, 2020June 30, 2024FUJIMORI, DANICA GALONICreporter.nih.gov
Engineered Ensemble Nanoimmunotherapies for CancerNIHNational Cancer Institute2021 to 2024$1,699,559February 1, 2023January 31, 2025FERNANDES, ROHANreporter.nih.gov
NP855 for Targeting Thyrointegrin αvβ3 receptors and Norepinephrine Transporter in Neuroblastoma ManagementNIHNational Cancer Institute2024 to 2025$1,661,800September 19, 2024August 31, 2027DAVIS, PAULreporter.nih.gov
Cell lineage as an indicator of immune response in neuroblastomaNIHNational Cancer Institute2022 to 2025$1,593,136June 16, 2022May 31, 2027GEORGE, RANI E.reporter.nih.gov
Mechanisms and Modeling of Neuroblastoma-Associated ATRX AlterationsNIHNational Institute of Neurological Disorders and Stroke2021 to 2024$1,591,835March 1, 2020December 31, 2024BERNSTEIN, EMILYreporter.nih.gov
BCL11B activation as an approach for enhancing the efficacy of immunotherapyNIHNational Institute of Allergy and Infectious Diseases2021 to 2024$1,566,114February 11, 2021July 1, 2024PAREKH, CHINTANreporter.nih.gov
GEARBOx - a multisite clinical trial matching tool for children with relapsed or refractory cancerNIHNational Cancer Institute2022 to 2024$1,551,911September 21, 2022August 31, 2025VOLCHENBOUM, SAMUELreporter.nih.gov
Targeting Shared Vulnerabilities in Alternate Telomere Lengthening (ALT) CancersNIHNational Cancer Institute2022 to 2025$1,509,510January 1, 2022August 31, 2027REYNOLDS, CHARLES PATRICKreporter.nih.gov
Identifying opportunities for extracellular inhibition of ALK signalingNIHNational Cancer Institute2021 to 2024$1,505,804September 1, 2020May 31, 2025KLEIN, DARYL EWALDreporter.nih.gov
Clinical Implications of Natural Killer-derived exosomal miRNAs in NeuroblastomaNIHNational Cancer Institute2024 to 2025$1,485,440April 1, 2024March 31, 2029FABBRI, MULLERreporter.nih.gov
Novel Health Equity Intervention to Improve Pediatric Oncology Outcome Disparities: Targeting Poverty and Psychosocial StressNIHNational Cancer Institute2022 to 2023$1,449,123March 1, 2022February 29, 2028BONA, KIRA O.reporter.nih.gov
Interplay between low levels of GAS7 expression and MYCN overexpression and its impact on neuroblastoma metastasisNIHNational Cancer Institute2021 to 2024$1,422,117July 15, 2020June 30, 2026ZHU, SHIZHENreporter.nih.gov
Developing novel CAR T cell designs using combinatorial antigen detectionNIHNational Cancer Institute2021 to 2025$1,421,654April 1, 2021March 31, 2026ALLEN, GREG MANESSreporter.nih.gov
Genetic pleiotropy across pediatric cancers, and cancer-related outcomesNIHNational Cancer Institute2024 to 2025$1,395,864May 16, 2024April 30, 2029WANG, ZHAOMINGreporter.nih.gov
Integrating Epidemiologic and Genomic Data to Elucidate the Genetic Overlap Between Congenital Anomalies and Pediatric CancerNIHNational Cancer Institute2023 to 2025$1,394,210September 19, 2023August 31, 2028HUFF, CHAD DANIELreporter.nih.gov
CAMKV Kinase Signaling in NeuroblastomaNIHNational Institute of Neurological Disorders and Stroke2022 to 2024$1,302,698August 15, 2020May 31, 2026YANG, JIANHUAreporter.nih.gov
GPC2 CARs in neuroblastoma: Mechanisms of resistance and efficacy of next-generation constructsNIHNational Cancer Institute2024 to 2025$1,259,856April 1, 2024March 31, 2029BOSSE, KRISTOPHER Rreporter.nih.gov
Linking nucleotide and amino acid metabolism to cholesterol synthesis by MYCNNIHNational Cancer Institute2021 to 2024$1,256,692February 1, 2020March 31, 2026DING, HAN-FEIreporter.nih.gov
COMBINATION HIGH-LET MOLECULAR RADIOTHERAPY OF RELAPSED REFRACTORY NEUROBLASTOMANIHNational Cancer Institute2024 to 2025$1,237,513September 17, 2024August 31, 2029ZHANG, HANWENreporter.nih.gov
Targeting Oncogenic ALK Signaling in NeuroblastomaNIHNational Cancer Institute2021 to 2023$1,229,101July 1, 2009June 30, 2025MOSSE, YAEL Preporter.nih.gov
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine TumorsNIHNational Cancer Institute2024 to 2025$1,227,146July 1, 2024June 30, 2029ZEPEDA-OROZCO, DIANAreporter.nih.gov
Development of Novel Acoustic Clusters for Improving Combinatorial Neuroblastoma TherapyNIHNational Cancer Institute2021 to 2023$1,226,418March 12, 2019February 28, 2025SIRSI, SHASHANK RAMESHreporter.nih.gov
Dissecting high-risk cell states in neuroblastomaNIHNational Cancer Institute2024 to 2025$1,205,608March 1, 2024February 28, 2029DURBIN, ADAM DAVIDreporter.nih.gov
Targeting retrotransposons for improved treatment of refractory childhood cancerNIHNational Cancer Institute2024 to 2025$1,186,599June 5, 2024May 31, 2029GUDKOV, ANDREI Vreporter.nih.gov
PARP-1 as a novel target for alpha-particle therapy in high-risk NeuroblastomaNIHNational Cancer Institute2021 to 2022$1,172,239May 1, 2018April 30, 2024PRYMA, DANIEL A.reporter.nih.gov
Cancer-specific dependencies within the NuRD chromatin remodeler complex: new targets and chemical toolsNIHNational Cancer Institute2024 to 2025$1,151,174January 1, 2024December 31, 2028ERB, MICHAEL Areporter.nih.gov
Tumor and host immune signatures associated with patient outcomes to GD2 chemoimmunotherapy in neuroblastomaNIHNational Cancer Institute2024 to 2025$1,145,381July 2, 2024June 30, 2029GOLDSMITH, KELLY Creporter.nih.gov
MYC activation in tumor progression of neuroblastomaNIHNational Cancer Institute2021 to 2023$1,119,259January 1, 2019June 30, 2025KANG, MIN HEEreporter.nih.gov
Circulating biomarkers of clinical response to combination targeted therapies in neuroblastomaNIHNational Cancer Institute2024 to 2025$1,113,986April 1, 2024March 31, 2029VO, KIEUHOA TRANreporter.nih.gov
Phase Changing Ultrasound Contrast Agents for Deep Tissue Imaging of Cellular ImmunotherapiesNIHNational Cancer Institute2024 to 2025$1,109,609September 10, 2024August 31, 2029MEDINA, SCOTT HAMMONDreporter.nih.gov
Development of a novel MYC inhibitor for cancer therapyNIHNational Cancer Institute2025$1,102,729September 12, 2025August 31, 2027VOLLRATH, BENreporter.nih.gov
DNA-Protein Crosslinks and Genomic InstabilityNIHNational Cancer Institute2021 to 2023$1,076,589January 1, 2019April 30, 2024SCHELLENBERG, MATTHEW Jreporter.nih.gov
Neuroblastoma reliance on DNMT1 through amplified MYCNNIHNational Cancer Institute2021 to 2023$1,051,198June 1, 2020May 31, 2025FABER, ANTHONY CHARLESreporter.nih.gov
Towards Novel Differentiation Therapies for Neuroblastoma.NIHNational Cancer Institute2021 to 2024$1,022,242May 1, 2019April 30, 2025BARBIERI, EVELINEreporter.nih.gov
NexTGen - STANFORDNIHNational Cancer Institute2022 to 2024$1,019,396June 1, 2024May 31, 2025WEISSMAN, IRVING L.reporter.nih.gov
Targeting EP300, a selective dependency in neuroblastomaNIHNational Cancer Institute2021 to 2024$1,011,846September 14, 2020August 31, 2025DURBIN, ADAM DAVIDreporter.nih.gov
Integrating targeted and immunotherapy to treat genetically heterogeneous cancersNIHNational Cancer Institute2021$1,010,431August 17, 2017July 31, 2022WEISS, WILLIAM Areporter.nih.gov
Spatial and single cell analysis of tumor microenvironment by seqFISH+NIHNational Cancer Institute2021$999,999April 1, 2020March 31, 2022FRIEDA, KIRSTENreporter.nih.gov
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.NIHNational Cancer Institute2021$999,883September 7, 2020August 31, 2022SCHULTZ, MICHAEL KINGreporter.nih.gov
ABT-199 based therapies to treat neuroblastomaNIHNational Cancer Institute2024 to 2025$997,984April 1, 2017May 31, 2029FABER, ANTHONY CHARLESreporter.nih.gov
A New Paradigm to Prevent and Treat MicrometastasesNIHNational Cancer Institute2024 to 2025$995,678February 1, 2024January 31, 2029CRIPE, TIMOTHY Preporter.nih.gov
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastomaNIHNational Cancer Institute2021 to 2023$942,428April 15, 2018March 31, 2025DUBOIS, STEVENreporter.nih.gov
Enhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeNIHNational Cancer Institute2021$913,712August 1, 2015July 31, 2023SONDEL, PAUL Mreporter.nih.gov
MYCN drives a druggable SUMOylation program in neuroblastomaNIHNational Cancer Institute2024 to 2025$864,114January 1, 2024December 31, 2028FABER, ANTHONY CHARLESreporter.nih.gov
Rewired Metabolism and Immunosuppression in MYCN-driven NeuroblastomaNIHNational Cancer Institute2024 to 2025$850,521August 15, 2024July 31, 2029BARBIERI, EVELINEreporter.nih.gov
cGAS-STING and therapeutic immune responses in neuroblastomaNIHNational Cancer Institute2022 to 2025$845,036September 1, 2022August 31, 2027WOLPAW, ADAM Jreporter.nih.gov
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in ChildrenNIHNational Cancer Institute2021 to 2022$818,770September 7, 2018August 31, 2024WANG, YINreporter.nih.gov
BCL11B activation as an approach for enhancing the efficacy of immunotherapyNIHNational Institute of Allergy and Infectious Diseases2024 to 2025$811,046February 11, 2021January 31, 2026PAREKH, CHINTANreporter.nih.gov
Investigating the relationship between Sympathetic Nervous System Development and NeuroblastomaNIHNational Institute of Neurological Disorders and Stroke2023 to 2025$795,000August 1, 2024April 30, 2029KASEMEIER, JENNIFERreporter.nih.gov
Targeting EP300 epigenomic control in neuroblastomaNIHNational Cancer Institute2025$768,713August 1, 2025July 31, 2030DURBIN, ADAM DAVIDreporter.nih.gov
Targeting splicing vulnerability of neuroblastomaNIHNational Cancer Institute2025$767,328August 1, 2025July 31, 2030YANG, JUNreporter.nih.gov
Direct Targeting of MYC in Cancer with Hyperstable Synthetic Transcriptional RepressorsNIHNational Cancer Institute2024 to 2025$755,740August 1, 2024July 31, 2029MOELLERING, RAYMOND Ereporter.nih.gov
Alternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targetsNIHNational Cancer Institute2021 to 2022$752,967August 29, 2018April 30, 2025REYNOLDS, CHARLES PATRICKreporter.nih.gov
Targeting the chromatin binding domains of BPTF for neuroblastoma epigenetic therapyNIHNational Cancer Institute2025$738,024January 1, 2025December 31, 2029FISCHER, MARCUSreporter.nih.gov
Radiation dosimetry for alpha-particle radiopharmaceutical therapy and application to pediatric neuroblastomaNIHNational Cancer Institute2023 to 2025$721,164December 10, 2021August 31, 2026BERTOLET REINA, ALEJANDROreporter.nih.gov
Targetable epigenetic modifiers that promote neuroblastoma malignancy and plasticityNIHNational Cancer Institute2025$718,113January 15, 2025December 31, 2029YANG, JUNreporter.nih.gov
Early phase clinical trials of 211At-meta-astatobenzylguanidine for children with neuroblastoma and adults with advanced neuroendocrine cancersNIHNational Cancer Institute2025$695,205June 1, 2025May 31, 2030NARAYAN, VIVEKreporter.nih.gov
Combining hu14.18-IL2 and NK cell infusions to treat neuroblastomaNIHNational Cancer Institute2021 to 2022$694,156July 3, 2018May 31, 2024CAPITINI, CHRISTIANreporter.nih.gov
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood CancersNIHNational Cancer Institute2021 to 2022$692,348September 20, 2018August 31, 2023MARIS, JOHN Mreporter.nih.gov
Targeting extracellular vesicles in neuroblastomaNIHNational Cancer Institute2025$690,013August 11, 2025July 31, 2030SPIEGELMAN, VLADIMIR S.reporter.nih.gov
Dissecting the contribution of the transcriptional regulators of SNS fate to neuroblastoma oncogenesisNIHNational Cancer Institute2021 to 2022$688,446June 1, 2018May 31, 2024FREEMAN, KEVIN W.reporter.nih.gov
Mechanisms of lmmunosuppression in MYCN-driven NeuroblastomaNIHNational Institute of Neurological Disorders and Stroke2025$635,173December 1, 2024November 30, 2029FENG, HUIreporter.nih.gov
Define the role of chromosome 17q gain in neuroblastoma malignancyNIHNational Cancer Institute2025$562,869January 1, 2025December 31, 2029HUANG, MILLERreporter.nih.gov
Discovering targets for neuroblastoma differentiation therapy from the human druggable genomeNIHNational Cancer Institute2025$531,550July 4, 2025June 30, 2028DU, LIQINreporter.nih.gov
PROTECT - Harnessing PROTEin Degradation for Advanced Childhood TumoursNIHNational Cancer Institute2024$506,676May 1, 2024April 30, 2026PFISTER, STEFANreporter.nih.gov
Assessing the efficacy of a ROR1:PD-L1:CD2 multispecific T cell engager in ROR1-positive and -negative neuroblastoma modelsNIHNational Cancer Institute2024$503,194September 1, 2024August 31, 2026OLSON, JAMES Mreporter.nih.gov
Characterizing and Targeting the Epigenetic Mechanisms Maintaining Neuroblastoma Tumor Initiating CellsNIHNational Cancer Institute2023$492,000December 1, 2022November 30, 2025AGARWAL, SAURABHreporter.nih.gov
Defining PRC1.1 as a gatekeeper of lineage plasticity and response to anti-GD2 therapyNIHNational Cancer Institute2024 to 2025$491,167May 9, 2023May 31, 2027MABE, NATHANIELreporter.nih.gov
Investigating SLC46A3 as a negative regulator of nanoparticle drug deliveryNIHNational Cancer Institute2024 to 2025$461,893July 5, 2024August 31, 2029STRAEHLA, JOELLE PAYNEreporter.nih.gov
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and CancerNIHNational Cancer Institute2021 to 2022$457,587December 27, 2017July 31, 2023DURDEN, DONALDreporter.nih.gov
Translation initiation as a therapeutic target in neuroblastomaNIHNational Cancer Institute2023 to 2024$453,511December 15, 2022November 30, 2024GEORGE, RANI E.reporter.nih.gov
CAMKV Kinase Signaling in NeuroblastomaNIHNational Institute of Neurological Disorders and Stroke2021 to 2022$453,407August 15, 2020July 10, 2022YANG, JIANHUAreporter.nih.gov
The function of TWIST1 acetylation in cell fate and tissue developmentNIHNational Institute of Dental & Craniofacial Research2023$448,500August 1, 2023July 31, 2025FAKHOURI, WALID D.reporter.nih.gov
Identifying neuroblastoma drivers and bringing them to the clinicNIHNational Cancer Institute2021$437,425April 2, 2021March 31, 2024SKAPEK, STEPHEN Xreporter.nih.gov
Manipulating Aberrant Calcium Signaling to Target Relapsed High-Risk NeuroblastomaNIHNational Cancer Institute2024$423,743March 1, 2024February 28, 2027KOOMOA, DANA-LYNN TAKEKOreporter.nih.gov
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastomaNIHNational Cancer Institute2021$413,844January 1, 2011February 28, 2023GEORGE, RANI E.reporter.nih.gov
NCI Research Specialist (Clinician Scientist) AwardNIHNational Cancer Institute2023 to 2025$411,489April 1, 2023March 31, 2028FOSTER, JENNIFER HAUNANIreporter.nih.gov
Development of small molecules to target KDM4BNIHNational Cancer Institute2021$410,606July 1, 2018June 30, 2022YANG, JUNreporter.nih.gov
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastomaNIHNational Cancer Institute2021 to 2022$404,390July 9, 2018June 30, 2023BOSSE, KRISTOPHER Rreporter.nih.gov
Salinomycin and its binding protein nucleolin in neuroblastomaNIHNational Cancer Institute2022 to 2023$403,097February 7, 2022January 31, 2024WU, ERXIreporter.nih.gov
ADEPT-STAR therapy for high risk neuroblastomaNIHNational Cancer Institute2023$400,000September 19, 2023August 31, 2024PETRICH, BRIAN Greporter.nih.gov
SBIR PHASE I TOPIC #446 - DEVELOPMENT OF SENOTHERAPEUTIC AGENTS FOR CANCER TREATMENTNIHNational Cancer Institute2023$400,000September 15, 2023September 14, 2024OHLMEYER, MICHAELreporter.nih.gov
Small Molecule N-myc Degraders as Novel Cancer Therapeutic AgentsNIHNational Cancer Institute2022$399,999April 5, 2022March 31, 2023FEI, DENNIS LIANGreporter.nih.gov
LGR5 antibody drug conjugate for the treatment of neuroblastomaNIHNational Cancer Institute2022 to 2023$396,739December 1, 2021November 30, 2024LIU, QINGYUNreporter.nih.gov
Development of deazaflavin analogs as potent and selective MRP1 inhibitors for cancer chemosensitizationNIHNational Cancer Institute2025$395,973September 5, 2025August 31, 2027XIE, JIASHUreporter.nih.gov
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and CancerNIHNational Cancer Institute2023$390,037December 27, 2017July 31, 2025DURDEN, DONALDreporter.nih.gov
Determining the significance of the N-MYC-WDR5 interaction in neuroblastoma.NIHNational Cancer Institute2021$379,815July 1, 2021June 30, 2024WEISSMILLER, APRIL M.reporter.nih.gov
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sitesNIHNational Cancer Institute2021 to 2023$377,685July 1, 2019June 30, 2024PATEL, RAVI BHASKERreporter.nih.gov
Clinical Significance and Mechanism of Action of Exosomal microRNAs in Neuroblastoma chemoresistanceNIHNational Cancer Institute2022$373,701January 1, 2018December 31, 2023FABBRI, MULLERreporter.nih.gov
Identifying and targeting oncogenic Myc enhancer control in pediatric tumorsNIHNational Cancer Institute2021$362,569April 1, 2017March 31, 2023WESTBROOK, THOMASreporter.nih.gov
SBIR CONCEPT AWARD - THERAPEUTICS - SULFONYL-UREA AND SULFONAMIDE PP2A ACTIVATORS AS MYCN AMPLIFIED NEUROBLASTOMA (NBL) THERAPEUTICSNIHNational Cancer Institute2024$355,000February 15, 2024February 14, 2025OHLMEYER, MICHAELreporter.nih.gov
Develop CTC capture technology for both mesenchymal and non-mesenchymal tumorsNIHNational Institute of Biomedical Imaging and Bioengineering2021$352,800May 1, 2018February 28, 2023LI, SHULINreporter.nih.gov
AlgenML: Drug target discovery platform for transcriptional reprogramming of MYCN-driven neuroblastomaNIHNational Institute of General Medical Sciences2021$350,000September 20, 2021August 31, 2025HUANG, CHUN-HAOreporter.nih.gov
Focal Sustained Release Chemotherapy-Loaded Biomaterials at Tumor SitesNIHNational Institute of Neurological Disorders and Stroke2021$342,398February 1, 2017November 30, 2021KAPLAN, DAVID L.reporter.nih.gov
Integrative analysis of multi-omics data to identify and characterize long noncoding RNA-derived fusions in pediatric cancerNIHOffice of the Director, National Institutes of Health2022$334,926September 20, 2022September 19, 2024ZHOU, CHANreporter.nih.gov
Identifying metabolic regulation of T cells during early childhood developmentNIHEunice Kennedy Shriver National Institute of Child Health & Human Development2024 to 2025$330,480April 1, 2024March 31, 2029ROWE, JARED H.reporter.nih.gov
Common Fund Gene Utility Compendium: A Systems Biology Resource to Explore Tissue-Specific Functional Genes and Druggable GenomesNIHOffice of the Director, National Institutes of Health2024$322,800September 5, 2024September 4, 2025LI, HUreporter.nih.gov
Targeted Radionuclide Therapy to Enhance the Efficacy of CAR T Cells Against NeuroblastomaNIHNational Cancer Institute2024 to 2025$319,272August 1, 2024July 31, 2029SODJI, QUAOVI Hreporter.nih.gov
Clinical significance and mechanism of action of exosomal microRNAs in Neuroblastoma chemoresistance.NIHNational Cancer Institute2021$316,635January 1, 2018June 27, 2021FABBRI, MULLERreporter.nih.gov
NextGen - CARDIFFNIHNational Cancer Institute2022 to 2024$301,996June 1, 2024May 31, 2025SEWELL, ANDREWreporter.nih.gov
Discovery of autoimmune antigens from non-coding sequencesNIHNational Institute of Allergy and Infectious Diseases2021 to 2022$296,882July 13, 2021June 30, 2025ROSENBERG, MIRIAM ISAACAreporter.nih.gov
Next Generation T cell therapies for childhood cancers (NexTGen)NIHNational Cancer Institute2023 to 2025$276,290June 1, 2025May 31, 2026YARMARKOVICH, MARKreporter.nih.gov
Identification of novel cooperating partners of MYCN in neuroblastoma tumorigenesisNIHNational Cancer Institute2021$248,999July 1, 2016August 31, 2023HUANG, MILLERreporter.nih.gov
PROTECT - Harnessing Protein Degradation for Advancing Childhood TumorsNIHNational Cancer Institute2024 to 2025$237,852May 1, 2024April 30, 2026JAN, MAXreporter.nih.gov
NexTGen - ICRNIHNational Cancer Institute2022 to 2023$230,695June 22, 2022May 31, 2025RABBITTS, TERRYreporter.nih.gov
Crosslinking Action of Chlorpyrifos Oxon as Mechanism of Chronic IllnessNIHNational Institute of Environmental Health Sciences2021$228,750January 6, 2020June 30, 2022LOCKRIDGE, OKSANAreporter.nih.gov
MYCN drives a suppressive tumor immune microenvironment in neuroblastoma.NIHNational Cancer Institute2025$225,101April 10, 2025March 31, 2027BARBIERI, EVELINEreporter.nih.gov
Elucidating transcription regulation by epigenetics in neuroblastomaNIHNational Cancer Institute2021$206,394April 1, 2018March 31, 2022APPLEBAUM, MARK ANDREWreporter.nih.gov
Molecular characterization of the functional isoforms of HLA-F in human health and cancerNIHNational Institute of Allergy and Infectious Diseases2021$196,548January 20, 2020December 31, 2021ADAMS, ERIN JUNEreporter.nih.gov
The role of CMTR2 in Lung CancerNIHNational Cancer Institute2021 to 2022$195,178September 21, 2016December 31, 2023YERMALOVICH, ALENAreporter.nih.gov
Molecular mechanisms driving cessation of neural crest migration and aggregation into cranial gangliaNIHNational Institute of Dental & Craniofacial Research2021 to 2025$192,657July 1, 2021July 2, 2025URRUTIA, HUGO ALEXANDERreporter.nih.gov
Studies of the structural and functional basis of neuroblastoma drug resistanceNIHNational Cancer Institute2021 to 2024$189,037January 1, 2021May 16, 2024PIETZ, HARLAN LINVERreporter.nih.gov
Radiation dosimetry for alpha-particle radiopharmaceutical therapy and application to pediatric neuroblastomaNIHNational Cancer Institute2022 to 2023$187,552December 10, 2021November 30, 2023BERTOLET REINA, ALEJANDROreporter.nih.gov
Pediatric Preclinical Testing ConsortiumNIHNational Cancer Institute2021$180,518July 7, 2015June 30, 2021MARIS, JOHN Mreporter.nih.gov
Long-read, single-cell RNA sequencing of high-risk neuroblastoma samplesNIHNational Cancer Institute2025$178,000January 1, 2025December 31, 2026THOMAS-TIKHONENKO, ANDREIreporter.nih.gov
Application of Gabriella Miller Kids First Pediatric Research Data to a Predictive Model of NeuroblastomaNIHEunice Kennedy Shriver National Institute of Child Health & Human Development2021$165,000April 1, 2021March 31, 2023KULESA, PAULreporter.nih.gov
DNA Topoisomerase Misfunctioning in Neurological DiseaseNIHNational Institute of Neurological Disorders and Stroke2021 to 2022$159,900January 1, 2021November 30, 2023NITISS, KARINreporter.nih.gov
Dissecting the mechanisms by which chromosomal instability impacts anti-Disialoganglioside responses in neuroblastomaNIHNational Cancer Institute2022 to 2024$158,420July 1, 2022June 30, 2025REBERNICK, RYANreporter.nih.gov
Probing INTS11 as a novel target in neuroblastomaNIHNational Cancer Institute2023 to 2024$154,000March 7, 2023February 28, 2025WAGNER, ERIC Jreporter.nih.gov
FLUORESCENT SENSORS FOR SUBCELLULAR COPPER IMAGING IN LIVE-CELLSNIHNational Institute of General Medical Sciences2021$151,000September 6, 2019July 31, 2023ABEBE, FASILreporter.nih.gov
NGTC - INSERMNIHNational Cancer Institute2022 to 2024$147,503June 1, 2024May 31, 2025DONNADIEU, EMMANUELreporter.nih.gov
Defining PRC1.1 as a gatekeeper of lineage plasticity and response to anti-GD2 therapyNIHNational Cancer Institute2023$147,150May 9, 2023May 31, 2024MABE, NATHANIELreporter.nih.gov
Elucidating the Role of Epigenetic Plasticity in anti-GD2 Immunotherapy ResponseNIHNational Cancer Institute2021 to 2022$137,784June 1, 2021May 31, 2024MABE, NATHANIELreporter.nih.gov
Protective Role of Nonclassical Monocytes in Immunotherapies for Solid CancersNIHNational Cancer Institute2021$136,148April 1, 2018March 31, 2022HEDRICK, CATHERINE Creporter.nih.gov
Cancer-associated fibroblasts and extracellular matrix remodeling in pediatric neuroblastomaNIHNational Cancer Institute2022 to 2024$131,420September 1, 2022August 31, 2025PETERSON, NICOLASreporter.nih.gov
Development of a novel dual inhibitor for treatment of MYCN-amplified neuroblastomaNIHNational Cancer Institute2025$131,300July 15, 2025May 31, 2027WEISSMILLER, APRIL M.reporter.nih.gov
PROTECT - Develop therapeutics to target oncogenic drivers of solid tumours in childrenNIHNational Cancer Institute2024$128,664May 1, 2024April 30, 2026CHESLER, LOUISreporter.nih.gov
Defining the mechanisms of B7-H3 overexpression and role in neuroblastoma metastasis and immune evasionNIHNational Cancer Institute2023 to 2025$121,560July 1, 2023June 30, 2026WINGROVE, CATHERINE LEONA-GRACEreporter.nih.gov
Intraoperative Molecular Imaging of Metastatic Osteosarcoma with 111In-dinutuximab-IR800NIHNational Cancer Institute2024 to 2025$119,554February 1, 2024June 30, 2025ROSENBLUM, LAUREN TAYLORreporter.nih.gov
Targeted therapy against TERT oncogene-rearranged neuroblastomaNIHNational Cancer Institute2021 to 2022$108,000August 1, 2021July 31, 2023LIU, TAOreporter.nih.gov
PROTECT - Harnessing PROTEin degradation for Advanced Childhood TumorsNIHNational Cancer Institute2024$101,568May 1, 2024April 30, 2026VON DELFT, FRANKreporter.nih.gov
PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors)NIHNational Cancer Institute2024$100,476May 1, 2024April 30, 2026ANDERSON, JOHNreporter.nih.gov
PROTECT - Harnessing PROTEin degradation for Advanced Childhood TumorsNIHNational Cancer Institute2024$86,618May 1, 2024April 30, 2026WIENKE, JUDITHreporter.nih.gov
Development of Glypican-2 redirected T cells for the Treatment of NeuroblastomaNIHNational Cancer Institute2021 to 2022$84,789January 1, 2021December 31, 2022BELL, MATTHEWreporter.nih.gov
Linking nucleotide and amino acid metabolism to cholesterol synthesis by MYCNNIHNational Cancer Institute2021$84,093February 1, 2020August 31, 2021DING, HAN-FEIreporter.nih.gov
Characterizing ALCAM as an oncoprotein and immunotherapeutic target in neuroblastomaNIHNational Cancer Institute2021 to 2022$80,240August 1, 2020July 31, 2023LINDSAY, JARRETTreporter.nih.gov
Elucidating the role of PATZ1 in MYCN-amplified neuroblastomaNIHNational Cancer Institute2025$78,040September 5, 2025September 4, 2028SOEUNG, MELINDAreporter.nih.gov
Developing novel ALK targeting therapies through the expansion of targeted protein degradationNIHNational Cancer Institute2025$78,040January 1, 2026December 31, 2028JOHNSON, SEANreporter.nih.gov
Credentialing Delta-like 3 (DLL3) as an oncoprotein and immunotherapeutic target in neuroblastomaNIHNational Cancer Institute2021 to 2022$75,823January 1, 2020October 31, 2022KENDSERSKY, NATHAN MICHAELreporter.nih.gov
Elucidating the role of the SAGA complex in MYCN-amplified neuroblastomaNIHNational Cancer Institute2021$74,886September 12, 2019September 11, 2022MALONE, CLARE FELICITYreporter.nih.gov
Elucidating the therapeutic tractability and functional role of SHP2 in ALK-driven high-risk neuroblastomaNIHNational Cancer Institute2021 to 2022$67,486September 1, 2020August 31, 2023GERELUS, MARKreporter.nih.gov
Degradation of the Nucleosome Remodeling Complex, NURF, with Bromodomain-Targeting Heterobifunctional MoleculesNIHNational Cancer Institute2021$29,672April 1, 2021September 8, 2021KIMBROUGH, JENNIFER Rreporter.nih.gov
Role of microRNAs released by Tumor Associated Macrophages within Exosomes in the chemoresistance of NeuroblastomaNIHNational Cancer Institute2021$11,688May 26, 2018June 27, 2021FABBRI, MULLERreporter.nih.gov
Investigating the relationship between Sympathetic Nervous System Development and NeuroblastomaNIHNational Institute of Neurological Disorders and Stroke2023$1May 15, 2023January 31, 2024KULESA, PAULreporter.nih.gov
Investigating SLC46A3 as a negative regulator of nanoparticle drug deliveryNIHNational Cancer Institute2024$1July 5, 2024September 30, 2024STRAEHLA, JOELLE PAYNEreporter.nih.gov

Organizations

OrganizationPlaceNIH awardsNIH amountNSF awardsNSF amount
Public Health InstituteOakland, CA2$168.9 million0$0
University of Southern CaliforniaLos Angeles, CA1$31.4 million0$0
Children's Hosp of PhiladelphiaPhiladelphia, PA15$27.4 million0$0
ST. Jude Children's Research HospitalMemphis, TN10$11.4 million0$0
Dana-Farber Cancer InstBoston, MA14$11 million0$0
Children's Hospital of Los AngelesLos Angeles, CA5$9.9 million0$0
University of California, San FranciscoSan Francisco, CA6$9.2 million0$0
Children's Research InstituteWashington, DC4$7.1 million0$0
Baylor College of MedicineHouston, TX8$7 million0$0
Seattle Children's HospitalSeattle, WA4$6.1 million0$0
Stanford UniversityStanford, CA3$6 million0$0
Salk Institute for Biological StudiesLa Jolla, CA1$5.7 million0$0
Columbia University Health SciencesNew York, NY2$5.7 million0$0
Research Inst Nationwide Children's HospColumbus, OH3$5.4 million0$0
University of ChicagoChicago, IL5$5.3 million0$0
Texas Tech University Health Scis CenterLubbock, TX4$5.2 million0$0
Virginia Commonwealth UniversityRichmond, VA4$5.2 million0$0
University of Pittsburgh at PittsburghPittsburgh, PA4$4 million0$0
University College LondonLondon2$3.7 million0$0
Spatial Genomics, Inc.Pasadena, CA2$3 million0$0
Viewpoint Molecular Targeting, Inc.Coralville, IA2$3 million0$0
Mayo Clinic RochesterRochester, MN3$2.8 million0$0
University of Tennessee Health Sci CTRMemphis, TN2$2.8 million0$0
University of PennsylvaniaPhiladelphia, PA6$2.2 million0$0
University of MinnesotaMinneapolis, MN3$2.2 million0$0
Johns Hopkins UniversityBaltimore, MD1$2.2 million0$0
University of California Los AngelesLos Angeles, CA1$2.1 million0$0
Cellectar Biosciences, Inc.Florham Park, NJ1$2 million0$0
University of California, San DiegoLa Jolla, CA1$2 million0$0
Vanderbilt UniversityNashville, TN1$2 million0$0
Oncternal Therapeutics, Inc.San Diego, CA1$1.9 million0$0
University of Wisconsin-MadisonMadison, WI3$1.9 million0$0
Cold Spring Harbor LaboratoryCold Spring Harbor, NY1$1.7 million0$0
University of TX MD Anderson Can CTRHouston, TX2$1.7 million0$0
George Washington UniversityWashington, DC1$1.7 million0$0
Nanopharmaceuticals, LLCRensselaer, NY1$1.7 million0$0
Icahn School of Medicine at Mount SinaiNew York, NY1$1.6 million0$0
Yale UniversityNew Haven, CT1$1.5 million0$0
University of Alabama at BirminghamBirmingham, AL1$1.3 million0$0
Washington UniversitySaint Louis, MO1$1.2 million0$0
University of Texas at DallasRichardson, TX1$1.2 million0$0
Roswell Park Cancer Institute CorpBuffalo, NY1$1.2 million0$0
Scripps Research Institute, theLa Jolla, CA1$1.2 million0$0
Massachusetts General HospitalBoston, MA3$1.1 million0$0
Emory UniversityAtlanta, GA1$1.1 million0$0
Pennsylvania State Univ University ParkUniversity Park, PA1$1.1 million0$0
Vortex Therapeutics INCLombard, IL1$1.1 million0$0
University of Texas HLTH Sci CTR HoustonHouston, TX2$845,2390$0
University of Maryland BaltimoreBaltimore, MD1$818,7700$0
Beckman Research Institute/city of HopeDuarte, CA1$811,0460$0
Children's Mercy Hosp (kansas City, Mo)Kansas City, MO1$795,0000$0
Atux Iskay Group LLCPlainsboro, NJ2$755,0000$0
Pennsylvania State Univ Hershey Med CTRHershey, PA1$690,0130$0
Boston University Medical CampusBoston, MA1$635,1730$0
Texas State University - San MarcosSan Marcos, TX1$531,5500$0
Middle Tennessee State UniversityMurfreesboro, TN2$511,1150$0
German Cancer Research CenterHeidelberg1$506,6760$0
ST. John's UniversityQueens, NY1$492,0000$0
Purdue UniversityWest Lafayette, IN1$491,1670$0
Carolinas Medical CenterCharlotte, NC1$457,5870$0
Ut Southwestern Medical CenterDallas, TX1$437,4250$0
Western New England UniversitySpringfield, MA1$423,7430$0
Baylor Research InstituteDallas, TX1$403,0970$0
Expression TherapeuticsTucker, GA1$400,0000$0
Stemsynergy Therapeutics, Inc.Miami, FL1$399,9990$0
Wake Forest University Health SciencesWinston-Salem, NC1$390,0370$0
The Institute of Cancer Research: Royal Cancer HospitalLondon2$359,3590$0
Algen Biotechnologies INCSan Francisco, CA1$350,0000$0
Tufts UniversityMedford, MA1$342,3980$0
Univ of Massachusetts Med SCH WorcesterWorcester, MA1$334,9260$0
University of HawaiiHonolulu, HI2$328,3230$0
Cardiff UniversityCardiff1$301,9960$0
Hebrew University of JerusalemJerusalem1$296,8820$0
New York University School of MedicineNew York, NY1$276,2900$0
University of Nebraska Medical CenterOmaha, NE1$228,7500$0
ST. Jude Children's Research Hospital Graduate School of Biomedical Sciences, LLCMemphis, TN2$216,2090$0
California Institute of TechnologyPasadena, CA1$192,6570$0
Weill Medical Coll of Cornell UnivNew York, NY1$189,0370$0
Stowers Institute for Medical ResearchKansas City, MO1$165,0000$0
University of Illinois at ChicagoChicago, IL1$159,9000$0
University of Michigan at Ann ArborAnn Arbor, MI1$158,4200$0
University of RochesterRochester, NY1$154,0000$0
Morgan State UniversityBaltimore, MD1$151,0000$0
Inserm Paris 5Paris1$147,5030$0
La Jolla Institute for ImmunologyLa Jolla, CA1$136,1480$0
University of New South WalesSydney1$108,0000$0
University of OxfordOxford1$101,5680$0
Prinses Maxima Voor Kinderoncologie, BVUtrecht1$86,6180$0
Augusta UniversityAugusta, GA1$84,0930$0
University of California-BerkeleyBerkeley, CA1$78,0400$0
University of Notre DameNotre Dame, IN1$10$0

Funding by fiscal year

Fiscal yearNIH awardsNIH amountNSF awardsNSF amount
202588$91,747,2710$0
2024102$88,496,9240$0
202386$79,780,1070$0
202285$65,265,1970$0
202184$76,467,3140$0

Open federal funding opportunities

From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.

Open opportunityNumberAgencyListingClosesAward ceilingWhy it matches
Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)PA-24-254NIHJuly 12, 2027Not listedNotice number printed on 3 awards here
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)PAR-27-089NIH93.395November 2, 2026Not listedSame assistance listing 93.395 as 68 awards here
Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional)PAR-26-152NIH93.395November 11, 2026Not listedSame assistance listing 93.395 as 68 awards here
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed)PAR-27-088NIH93.395November 20, 2026Not listedSame assistance listing 93.395 as 68 awards here
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)PAR-24-214NIH93.395January 7, 2027$375,000Same assistance listing 93.395 as 68 awards here
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)PAR-25-079NIH93.395January 7, 2027$500,000Same assistance listing 93.395 as 68 awards here
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)PAR-25-081NIH93.395January 7, 2027$499,999Same assistance listing 93.395 as 68 awards here
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)RFA-CA-27-005NIH93.395January 11, 2027$700,000Same assistance listing 93.395 as 68 awards here
Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)PAR-27-009NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 68 awards here
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)RFA-CA-26-010NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 68 awards here
Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)RFA-CA-27-003NIH93.395January 25, 2027Not listedSame assistance listing 93.395 as 68 awards here
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)PA-27-100NIH93.395April 5, 2027Not listedSame assistance listing 93.395 as 68 awards here
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)PA-27-102NIH93.395April 5, 2027Not listedSame assistance listing 93.395 as 68 awards here
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)RFA-CA-28-003NIH93.395June 11, 2027$600,000Same assistance listing 93.395 as 68 awards here
Successor-in-Interest (Type 6 Parent Clinical Trial Optional)PA-24-253NIH93.395July 17, 2027Not listedSame assistance listing 93.395 as 68 awards here
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)PA-25-080NIH93.395September 7, 2027Not listedSame assistance listing 93.395 as 68 awards here
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)PAR-24-325NIH93.395September 7, 2027Not listedSame assistance listing 93.395 as 68 awards here
Investigator-Focused Award (Parent R35)PAR-28-037NIH93.395October 4, 2027Not listedSame assistance listing 93.395 as 68 awards here
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)RFA-CA-27-019NIH93.395October 19, 2027$300,000Same assistance listing 93.395 as 68 awards here
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)PAR-27-078NIH93.395October 25, 2027$375,000Same assistance listing 93.395 as 68 awards here

Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.